Having trouble reading this email View it in your browser.

StockBuru Blog: Skinvisible, Inc. (OTCBB: SKVI)

Skinvisible, Inc. (OTCBB: SKVI) Skinvisible Pharmaceuticals, Inc. (OTCBB:SKVI) and (OTCQB:SKVI) Feasibility Agreement with Major Pharmaceutical Company SKINVISIBLE PHARMACEUTICALS, INC. has entered into a feasibility agreement with Novartis Pharma AG Under the agreement Skinvisible will assess the technical feasibility of a topical formulation with an undisclosed compound utilizing its proprietary Invisicare® polymer delivery system. This formulation, if successful, would leverage Invisicare`s proprietary main benefits by providing controlled release of the proprietary active ingredient. Invisicare® is a versatile delivery system. The polymers deliver the active ingredient and bind to the skin resisting both wash-off and perspiration.

A good analogy in understanding the way SKVI`s Invisicare® works is that the polymer delivery system is the envelope that carries the letter or the active ingredient provided by Novartis to the skin in a controlled release format.

Invisicare® offers the following key benefits:

• Displays superior skin adherence for extended time periods • Non-occlusive yet resists water wash-off, respiration and perspiration • Offers advantage of controlled and/or sustained time-release • Highly compatible with a variety of actives and bases • Easy to emulsify • Formulates well as a cream, lotion, or spray viscosity • Non-irritating emulsion dries quickly with no greasy after-feel • Broad polymer selection to meet application requirements • Offers “Life Cycle” management to core products with potential for new patent The agreement includes the option for the two companies to enter into a future exclusive licensing agreement which would include both a licensing fee and royalties based on sales.

About Novartis Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group`s continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible`s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. www.skinvisible.com and www.invisicare.com .

Forward-Looking Statements: This release contains `forward looking` statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10K for the quarter ending October 31, 2010).

Contact: Skinvisible Pharmaceuticals, Inc.

Phone: 702-433-7154 Email: info@skinvisible.com

Contact Info:

Skinvisible Pharmaceuticals, Inc.

Doreen McMorran 702-433-7154 info@skinvisible.com  

Absolute Life Solutions American Energy Fields New Mexico Software Lexaria Corp MacroSolve Debt Resolve Medizone International About StockGuru: The original service that has become StockGuru started in the late `90`s. At first if was our publisher sharing picks with his friends. Then it grew. Then it became a formal list in 2001. In 2002 it became a web site. In 2003 it became StockGuru. READ ALL ABOUT IT HERE . .     Contact StockGuru: P: 469-358-5200 F: 214-975-1238 Publisher@StockGuru.com

This message was intended for “ You have received this message because you are subscribed to `Stock Guru` Pentony Enterprises LLC is STOCKGURU.COM. 1601 Berwick Drive, McKinney, Texas 75070 – (469) 252-3030. Disclosure: Pentony Enterprises LLC has covered SKVI before for compensation, however, today we are covering this release due to the recent activity in the stock and the significance of the news. Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract on July 12, 2010. The company paid us five thousand dollars per month in cash for the period one month. Pentony Enterprises LLC was previously compensated 500,000 144 restricted common shares by the company for profile coverage for the period ending January 30, 2010. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation that is share related during this period. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

<a href="http://www.sgurunews.com/emailmarketer/

OTCQB · SKVI

You are subscribed as

Trade Alert: Skinvisible, Inc. (OTCBB: SKVI)

Skinvisible, Inc. (OTCBB:SKVI) Dear Members, I just wanted to update you on Skinvisible, Inc. – OTCBB: SKVI.  I was reading their latest Form 10-Q filed about two weeks ago.  I think it gives a great understanding of the agreements with RHEI.  See below quoted from the that 10-Q – PAY PARTICULAR ATTENTION TO WHAT I HIGHLIGHTED IN RED.

FROM THE SKINVISIBLE 10-Q FILED NOV 15 2010:

Recent Developments   On June 30, 2010, we entered into an exclusive license agreement (“Agreement 1”) with RHEI Pharmaceuticals HK, Ltd. (“RHEI”), a Hong Kong-based pharmaceutical company and a subsidiary of the Luxembourg-based Leeward Ventures SICAR SCA.  Under the agreement, we granted to RHEI the exclusive rights to three of our formulations developed using the Invisicare polymer delivery system. The agreement specifies exclusivity for products in the institutional / healthcare market and includes an adult incontinence cream, skin barrier cream and super moisturizer. The agreement specifies upfront license fees for the territories of Europe and China and milestone payments based on approvals and launch dates for the United States. In addition, we will receive royalties on sales of the products. RHEI will be responsible for regulatory filings, manufacturing and commercialization of the products. RHEI will leverage its affiliate BeoCare Group, a leading medical consumables manufacturer with facilities in the United States, Europe and China, to provide access to the institutional / healthcare markets through its established network of multi-national clients. Additionally, RHEI will also sell to its affiliate, Senior Assist NV, one of the largest assisted living providers in Belgium, with a chain of thirty-three seniors` homes. We have also entered into an exclusive licensing agreement (Agreement 2”) with RHEI on June 30, 2010 for the commercial/institutional rights for DermSafe® Hand Sanitizer for Europe and China. This agreement includes licensing fees payable in milestones based on regulatory approval in Europe and China, anticipated to occur within twelve months or less. RHEI will pay us a royalty on product sales and be responsible for seeking regulatory approval, manufacturing, and commercialization. We retain rights to DermSafe for the retail/consumer markets within Europe and China. This agreement also provides us with all data generated by RHEI to pursue regulatory approvals within the U.S. and internationally. On October 12, 2010, we and RHEI amended the above agreements entered into on June 30, 2010. RHEI has chosen to focus on DermSafe® as their priority product after having established a straightforward path to European approval added to an increased interest for an alcohol-free hand sanitizer in that territory. The amended agreements grant RHEI the exclusive right to distribute DermSafe® within Europe for commercial use only subject to RHEI paying a license fee of five hundred thousand US dollars (US$500,000).  We agreed to apply the two hundred and fifty thousand US dollars (US $250,000) license fee already paid by RHEI for Agreement 1 towards Agreement 2 for Europe and RHEI paid a further fifty thousand US dollars (US $50,000) with the balance owing of two hundred thousand US dollars (US $200,000) due upon RHEI making its first sale within the territory but no later than March 21, 2011. Agreement 1, which includes an adult incontinence cream, barrier cream and super moisturizer, remains in place and will now require the license fees to be paid upon launch. Agreement 1 will become non-exclusive effective immediately for the term of the agreement.  Should RHEI elect to pay the license fee prior to the expiration date of Agreement 1, the license fee will be due immediately and Agreement 1 will become exclusive for RHEI for that territory. While Agreement 1 remains non-exclusive, we have the right to enter into an exclusive agreement with another party other than RHEI for Europe, China or the US. These two new agreements with RHEI will pay us $1.5 million in licensing fees if all milestones are met and no later than June 30, 2011. In addition we will receive royalties on their product sales plus revenue from the Invisicare polymer required to make the products. (fully explained above).

(END OF CITATION FROM 10-Q) That is higly significant and will make a very meaningful addition to the bottom line. We will keep you updated!

Live Twitter Alerts All Market Day Our Twitter Feed includes all live posts from StockGuru.com.

Featured on StockGuru While we cover many companies, here are our current featured profiles on StockGuru:   Gold American Mining Corp. (OTCBB: SILA)

Liberty Energy Corp. (OTCBB: LBYE) Debt Resolve, Inc. (OTCBB: DRSV)

MacroSolve, Inc. (OTCBB: MCVE) APC Group, Inc.

(OTC: APCU) Industrial Nanotech (OTC: INTK) Medizone International (OTCBB: MZEI

StockGuru Spotlight Alerts Here are our latest Spotlight Alerts. Note that we typically do NOT email these to members. You must visit the site at THIS LINK to keep up to date; or you may subscribe to THIS RSS FEED .

<a href="http://www.sgurunews.com/emailmarketer/

APCU · DRSV · FILED · INTK · LBYE · MCVE · MZEI · RHEI · SICAR · SILA · SKVI

You are subscribed as

Breaking News: Vicor Technologies, Inc. (OTCBB: VCRT)

Vicor Technologies, Inc. (OTCBB: VCRT)

StockGuru Trade Alert – Huge Release Issued Wednesday on Vicor Technologies (OTCBB: VCRT) – Dell Official Quoted as Vicor Selects Dell as Worldwide IT Hardware Partner for Its PD2i Analyzer(TM)

It was last December when I brought you Vicor Technologies (OTCBB: VCRT) for the first time. It is a company that has the extraordinary ability to diagnose risk when it comes to reading EKG’s. Now, that greatly simplifies the story. I encourage you to watch the interview we conducted in first quarter of this year. SEE IT HERE ON OUR SHAREHOLDER VISION SITE . What is extraordinary just yesterday is a press release that show how close the company is to fully commercializing the PD2i Analyzer™ through an newly announced strategic relationship with Dell, Inc. Note that a company as significant as Dell is absolutely not going to let a small cap stock name their company in a press release if it is not real and substantial. Yesterday’s release went a step further than that: A Dell spokesperson is even quoted in the release. I will show you the quote… but I encourage you to read the full press release below.

“Dell Healthcare and Life Sciences is proud to be chosen as Vicor’s worldwide IT solutions provider. Dell is committed to developing and supporting healthcare IT solutions to improve care and delivery,” stated Scott Jenkins, PhD, Vice President, Dell, Inc.

“We’re thrilled to have Dell as our worldwide IT solutions partner. Dell’s well-established reputation for creating innovative technologies and business solutions, strong internal development capabilities, global reach, and consumer-centric approach make it the perfect worldwide IT solutions partner for Vicor,” stated Mr. Fater. “Given the growing amount of positive feedback we’re receiving from physicians and cardiologists using the PD2i Analyzer™ to enhance diagnosis of those at risk of cardiac death from arrhythmia or pump failure, as well as autonomic neuropathy, we’re extremely optimistic about the prospects for the PD2i Analyzer™ and PD2i CA™ worldwide. These diagnostics have enabled the physicians and cardiologists using them to use existing CPT codes for reimbursement, strengthened their ability to diagnose difficult to identify conditions, and enabled early, sometimes life-saving treatment,” Mr. Fater concluded.

Obviously this is a huge development. Read the full release. Read my disclosure at the bottom. I still hold all shares.

Vicor Technologies’ Selects Dell to Serve as Worldwide IT Hardware Partner for Its PD2i Analyzer(TM) BOCA RATON, FL, Oct 06, 2010 (MARKETWIRE via COMTEX) — David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor has selected Dell’s Healthcare and Life Sciences division to serve as its worldwide hardware partner for the Company’s PD2i Analyzer(TM) and PD2i CA(TM) (Cardiac Analyzer). According to the terms of the agreement, Dell will create Vicor-labeled laptop computers specifically customized to Vicor’s specifications and package them for Vicor’s worldwide distribution. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i(R) nonlinear algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i(R) nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events, including congestive heart failure patients for cardiac death resulting from arrhythmia or pump failure, diabetics for diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention. “Dell Healthcare and Life Sciences is proud to be chosen as Vicor’s worldwide IT solutions provider. Dell is committed to developing and supporting healthcare IT solutions to improve care and delivery,” stated Scott Jenkins, PhD, Vice President, Dell, Inc. “We’re thrilled to have Dell as our worldwide IT solutions partner. Dell’s well-established reputation for creating innovative technologies and business solutions, strong internal development capabilities, global reach, and consumer-centric approach make it the perfect worldwide IT solutions partner for Vicor,” stated Mr. Fater. “Given the growing amount of positive feedback we’re receiving from physicians and cardiologists using the PD2i Analyzer(TM) to enhance diagnosis of those at risk of cardiac death from arrhythmia or pump failure, as well as autonomic neuropathy, we’re extremely optimistic about the prospects for the PD2i Analyzer(TM) and PD2i CA(TM) worldwide. These diagnostics have enabled the physicians and cardiologists using them to use existing CPT codes for reimbursement, strengthened their ability to diagnose difficult to identify conditions, and enabled early, sometimes life-saving treatment,” Mr. Fater concluded. About Vicor Technologies, Inc. Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i(R)). The PD2i(R) nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations. The PD2i Analyzer(TM), which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer(TM) are able to receive reimbursement under existing CPT codes. The PD2i VS(TM) (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA(TM) (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure. Vicor anticipates developing additional applications utilizing the PD2i(R) nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com. Disclaimer The appearance in this release of name-brand institutions, such as Dell and the U.S. Army Institute for Surgical Research, does not constitute endorsement by these institutions of the information, products, or services contained therein. Caution Regarding Forward-Looking Statements Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer(TM); our ability to obtain FDA approval of our 510(k) submission to secure a marketing claim for the PD2i CA(TM)(Cardiac Analyzer) for testing patients for cardiovascular disease and our ability to obtain marketing clearance from the FDA for the PD2i VS(TM) (Vital Sign) for military and civilian applications; our ability to obtain the necessary regulatory approvals to market in the People’s Republic of China; our ability to develop additional applications for the PD2i(R) algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to successfully complete the normal range study for PD2i(R) values; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Vicor Technologies, Inc. (OTCBB: VCRT)

Introduction Vicor Technologies, Inc. (OTCBB: VCRT) is in the crucial transformative stage for a biotechnology company on the verge of becoming a viable commercial enterprise. This biotechnology company is focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i™ nonlinear algorithm and software which is:

Highly accurate Provides user friendly data acquisition Effective for trauma triage easily deployed in a portable monitor Provides a simple noninvasive test for identifying patients at risk of sudden cardiac death Provides a simple noninvasive test for identifying patients with Diabetic Autonomic Neuropathy

The PD2i Algorithm and software risk stratifies target populations to predict future pathological events. As a predictor of sudden cardiac death it has been shown to be highly accurate, with a sensitivity approaching 100% and a specificity of ~86%. The advantage of the PD2i™ nonlinear algorithm is that it typically uses recordings made at rest and does not require stress-testing or any active participation from the patient. The test is relatively impervious to data non-stationarities and artifacts, setting it apart from other measures with unparalleled sensitivity. A large physician shareholder base represents the early adoptees of this Company.

A new vital sign with the ability to actually save lives in both combat and civilian setting The PD2i Analyzer™ can capture and display Heart Rate Variability (see defined below) in patients at rest and during paced respiration and controlled exercise. Able to identify trauma victims in need of an immediate lifesaving intervention Able to be used along with other clinical data to identify patients at risk of sudden cardiac death Able to be used along with other clinical data to identify patients who have autonomic dysfunction Able to improve trauma triage in real world situations and on the battlefield where time is of the essence and the collection of ‘clean’ data is never guaranteed Able to provide consistently accurate results which requires just one to two minutes of EKG data in a trauma setting Not derailed in delivering actionable results by noisy raw EKG data Functional in trauma environments and battlefield situations

Live Twitter Alerts All Market Day Our Twitter Feed includes all live posts from StockGuru.com.

Featured on StockGuru While we cover many companies, here are our current featured profiles on StockGuru:   Kentucky Energy, Inc.

(OTC: QMIN) Skinvisible, Inc.

(OTCBB: SKVI) Industrial Nanotech (OTC: INTK) Medizone International (OTCBB: MZEI)

StockGuru Spotlight Alerts Here are our latest Spotlight Alerts. Note that we typically do NOT email these to members. You must visit the site at THIS LINK to keep up to date; or you may subscribe to THIS RSS FEED .  

Suggest a Client: Do you know a great company that simply must be featured on StockGuru or Shareholder Vision Suggest it to us. Email: john@stockguru.com Tel: (469) 252-3031.

<a href="http://www.sgurunews.com/emailmarketer/

INTK · MZEI · QMIN · SKVI · VCRT

You are subscribed as

Breaking News: Industrial Nanotech, Inc. (Symbol: INTK)

STOCKGURU PROFILE – CORPORATE WEB SITE Trade Alert:  INTK Up 19% on Very Substantial Volume – This follows Earlier Alert on StockGuru MOST RECENT NEWS:

Industrial Nanotech, Inc. Announces Revenue for Q3 2010: Approximately $1,036,047.00 US NAPLES, Fla., Oct 06, 2010 (BUSINESS WIRE) — Industrial Nanotech, Inc. (Pink Sheets:INTK), an emerging global leader in nanoscience energy saving solutions, today announced that the sales revenue for the 3 month period ending September 30, 2010 was $1,036,047.00 US. “The change in the economic conditions that we all experienced in 2009 forced us to rethink, revise and retool our strategy and supplement the reduced revenue from the homeowner Do-It-Yourself market with increased focus on the longer sales cycle major industrial corporations,” states Stuart Burchill, CEO/CTO of Industrial Nanotech, Inc. “Fortunately, we had spent the previous five years diligently and methodically establishing proof of the value added proposition that our technology provides to industries around the world, including the fact that it pays for itself in typically 6-18 months by significantly reducing energy consumption and improving critical sustainability initiatives. Our patented Nansulate product line of award winning, energy saving protective specialty coatings containing a nanotechnology based material are well-documented to provide the combined performance qualities of thermal insulation, corrosion prevention, resistance to mold growth, fire resistance, chemical resistance and lead encapsulation in an environmentally safe, water-based, coating formulation.” Mr. Burchill continued, “Armed with an innovative, sustainable product line and solid data to back up its extraordinary performance and case studies of companies saving more in just the first year than the product cost them, plus the additional savings year after year, we just worked harder and smarter to get the message out to major global industrial companies and the results are testimonial to our strategy. Our technology simply offers value in cost savings, energy savings and carbon footprint reduction which companies are recognizing and implementing. We have reason to be optimistic about both the near term and long term likelihood of continued growth and success and we look forward to continuing to serve our customers well and enhance our shareholder value.”

Nansulate(R) is the Company`s patented product line of award winning, specialty coatings containing a nanotechnology based material and which are well-documented to provide the combined performance qualities of thermal insulation, corrosion prevention, resistance to mold growth, fire resistance, chemical resistance and lead encapsulation in an environmentally safe, water-based, coating formulation. The Nansulate(R) Product Line includes industrial, residential, agricultural and solar thermal insulation coatings. Additional information about the Company and its products can be found at their websites, ( www.industrial-nanotech.com ) and ( www.nansulate.com ). Blog: www.nansulate.com/nanoblog , Twitter: www.twitter.com/NanoPioneer , Search `Nansulate` on Facebook.

Industrial Nanotech Inc. is a global nanoscience solutions and research leader and member of the U.S. Greenbuilding Council, the American Solar Energy Society, and an official ALLY organization with the U.S. Dept. of Energy “Save Energy Now” program. The Company develops and commercializes new and innovative applications for sustainable nanotechnology which are sold worldwide.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

CONTACT:

For Industrial Nanotech, Inc. Investor Relations: Rob Karbowsky, 800-767-3998 investini@industrial-nanotech.com

Copyright Business Wire 2010

OTC: INTK

Visit StockGuru for the Full Profile for INTK

Live Twitter Alerts All Market Day Our Twitter Feed includes all live posts from StockGuru.com.

Featured on StockGuru While we cover many companies, here are our current featured profiles on StockGuru:  

Kentucky Energy, Inc.

(OTC: QMIN) Skinvisible, Inc.

(OTCBB: SKVI) Industrial Nanotech (OTC: INTK) Medizone International (OTCBB: MZEI)  

StockGuru Spotlight Alerts Here are our latest Spotlight Alerts. Note that we typically do NOT email these to members. You must visit the site at THIS LINK to keep up to date; or you may subscribe to THIS RSS FEED .  

Suggest a Client: Do you know a great company that simply must be featured on StockGuru or Shareholder Vision Suggest it to us. Email: john@stockguru.com Tel: (469) 252-3031.

<a href="http://www.sgurunews.com/emailmarketer/

ALLY · INTK · MZEI · QMIN · SKVI

You are subscribed as

Breaking News: Industrial Nanotech, Inc. (Symbol: INTK)

STOCKGURU PROFILE – CORPORATE WEB SITE Trade Alert:  INTK Up 19% on Very Substantial Volume – This follows Earlier Alert on StockGuru MOST RECENT NEWS:

Industrial Nanotech, Inc. Announces Revenue for Q3 2010: Approximately $1,036,047.00 US NAPLES, Fla., Oct 06, 2010 (BUSINESS WIRE) — Industrial Nanotech, Inc. (Pink Sheets:INTK), an emerging global leader in nanoscience energy saving solutions, today announced that the sales revenue for the 3 month period ending September 30, 2010 was $1,036,047.00 US. “The change in the economic conditions that we all experienced in 2009 forced us to rethink, revise and retool our strategy and supplement the reduced revenue from the homeowner Do-It-Yourself market with increased focus on the longer sales cycle major industrial corporations,” states Stuart Burchill, CEO/CTO of Industrial Nanotech, Inc. “Fortunately, we had spent the previous five years diligently and methodically establishing proof of the value added proposition that our technology provides to industries around the world, including the fact that it pays for itself in typically 6-18 months by significantly reducing energy consumption and improving critical sustainability initiatives. Our patented Nansulate product line of award winning, energy saving protective specialty coatings containing a nanotechnology based material are well-documented to provide the combined performance qualities of thermal insulation, corrosion prevention, resistance to mold growth, fire resistance, chemical resistance and lead encapsulation in an environmentally safe, water-based, coating formulation.” Mr. Burchill continued, “Armed with an innovative, sustainable product line and solid data to back up its extraordinary performance and case studies of companies saving more in just the first year than the product cost them, plus the additional savings year after year, we just worked harder and smarter to get the message out to major global industrial companies and the results are testimonial to our strategy. Our technology simply offers value in cost savings, energy savings and carbon footprint reduction which companies are recognizing and implementing. We have reason to be optimistic about both the near term and long term likelihood of continued growth and success and we look forward to continuing to serve our customers well and enhance our shareholder value.”

Nansulate(R) is the Company`s patented product line of award winning, specialty coatings containing a nanotechnology based material and which are well-documented to provide the combined performance qualities of thermal insulation, corrosion prevention, resistance to mold growth, fire resistance, chemical resistance and lead encapsulation in an environmentally safe, water-based, coating formulation. The Nansulate(R) Product Line includes industrial, residential, agricultural and solar thermal insulation coatings. Additional information about the Company and its products can be found at their websites, ( www.industrial-nanotech.com ) and ( www.nansulate.com ). Blog: www.nansulate.com/nanoblog , Twitter: www.twitter.com/NanoPioneer , Search `Nansulate` on Facebook.

Industrial Nanotech Inc. is a global nanoscience solutions and research leader and member of the U.S. Greenbuilding Council, the American Solar Energy Society, and an official ALLY organization with the U.S. Dept. of Energy “Save Energy Now” program. The Company develops and commercializes new and innovative applications for sustainable nanotechnology which are sold worldwide.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

CONTACT:

For Industrial Nanotech, Inc. Investor Relations: Rob Karbowsky, 800-767-3998 investini@industrial-nanotech.com

Copyright Business Wire 2010

OTC: INTK

Visit StockGuru for the Full Profile for INTK

Live Twitter Alerts All Market Day Our Twitter Feed includes all live posts from StockGuru.com.

Featured on StockGuru While we cover many companies, here are our current featured profiles on StockGuru:  

Kentucky Energy, Inc.

(OTC: QMIN) Skinvisible, Inc.

(OTCBB: SKVI) Industrial Nanotech (OTC: INTK) Medizone International (OTCBB: MZEI)  

StockGuru Spotlight Alerts Here are our latest Spotlight Alerts. Note that we typically do NOT email these to members. You must visit the site at THIS LINK to keep up to date; or you may subscribe to THIS RSS FEED .  

Suggest a Client: Do you know a great company that simply must be featured on StockGuru or Shareholder Vision Suggest it to us. Email: john@stockguru.com Tel: (469) 252-3031.

<a href="http://www.sgurunews.com/emailmarketer/

ALLY · INTK · MZEI · QMIN · SKVI